Show simple item record

dc.contributor.authorMuñoz Manchado, Ana Belén 
dc.contributor.authorVilladiego, Javier
dc.contributor.authorRomo-Madero, S.
dc.contributor.authorSuárez Luna, Nela
dc.contributor.authorBermejo-Navas, A.
dc.contributor.authorRodríguez-Gómez, J.A.
dc.contributor.authorGarrido-Gil, P.
dc.contributor.authorLabandeira-García, J.L.
dc.contributor.authorEchevarría, M.
dc.contributor.authorLópez Barneo, José
dc.contributor.authorToledo Aral, Juan J.
dc.contributor.otherAnatomía Patológica, Biología Celular, Histología, Historia de la Ciencia, Medicina Legal y Forense y Toxicologíaes_ES
dc.date.accessioned2024-09-27T12:39:01Z
dc.date.available2024-09-27T12:39:01Z
dc.date.issued2016
dc.identifier.issn1471-4159
dc.identifier.issn0022-3042
dc.identifier.urihttp://hdl.handle.net/10498/33428
dc.description.abstractDespite the different animal models of Parkinson's disease developed during the last years, they still present limitations modelling the slow and progressive process of neurodegeneration. Here, we undertook a histological, neurochemical and behavioural analysis of a new chronic parkinsonian mouse model generated by the subcutaneous administration of low doses of MPTP (20 mg/kg, 3 times per week) for 3 months, using both young adult and aged mice. The MPTP-induced nigrostriatal neurodegeneration was progressive and was accompanied by a decrease in striatal dopamine levels and motor impairment. We also demonstrated the characteristic neuroinflammatory changes (microglial activation and astrogliosis) associated with the neurodegenerative process. Aged animals showed both a faster time course of neurodegeneration and an altered neuroinflammatory response. The long-term systemic application of low MPTP doses did not induce any increase in mortality in either young adult or aged mice and better resembles the slow evolution of the neurodegenerative process. This treatment could be useful to model different stages of Parkinson's disease, providing a better understanding of the pathophysiology of the disease and facilitating the testing of both protective and restorative treatments. Here, we show a new chronic and progressive parkinsonian mouse model, in young and aged mice. This model produces a stable degeneration of the dopaminergic nigrostriatal pathway, continuous neuroinflammatory reaction and motor deficits. Aged animals showed a faster neurodegeneration and an altered neuroinflammatory response. This treatment could be useful to model different stages of PD and to test both protective and restorative therapeutic approaches.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherWilleyes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceJournal of Neurochemistry, Vol. 136, Núm. 2, 2016, pp. 373-387es_ES
dc.subjectMPTPes_ES
dc.subjectParkinson's diseasees_ES
dc.subjectageinges_ES
dc.subjectanimal modelses_ES
dc.subjectdopaminees_ES
dc.subjectneuroinflammationes_ES
dc.titleChronic and progressive Parkinson's disease MPTP model in adult and aged micees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1111/jnc.13409
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional